Sequencing and Combining Targeted Therapies in Melanoma

Clinical Pearls

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses sequencing and combining targeted therapies in the treatment of melanoma.

• Because of their ability to induce a rapid response and palliative benefit, targeted therapies should be used in patients with rapidly dividing disease, high tumor bulk, or poor performance status.
• Combining targeted therapies with immunotherapies is an appropriate way to achieve substantial progression-free survival benefit.